In Vitro Activity of Fidaxomicin (OPT-80) Tested against Contemporary Clinical Isolates of Staphylococcus spp. and Enterococcus spp.

被引：27
作者：
Biedenbach, Douglas J. [1 ]
Ross, James E. [1 ]
Putnam, Shannon D. [1 ]
Jones, Ronald N. [1 ]
机构：
[1] JMI Labs, Iowa City, IA 52317 USA
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2010年 / 54卷 / 05期
关键词：
VANCOMYCIN-RESISTANT ENTEROCOCCI; CLOSTRIDIUM-DIFFICILE INFECTION; ORAL METRONIDAZOLE; DISEASE;
D O I：
10.1128/AAC.00090-10
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
引用
收藏
页码：2273 / 2275
页数：3
相关论文
共 16 条
[1]   Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease [J].
Al-Nassir, Wafa N. ;
Sethi, Ajay K. ;
Li, Yuejin ;
Pultz, Michael J. ;
Riggs, Michelle M. ;
Donskey, Curtis J. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (07) :2403-2406
[2]  
[Anonymous], 1999, M26A CLIN LAB STAND
[3]   Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection [J].
Citron, D. M. ;
Babakhani, F. ;
Goldstein, E. J. C. ;
Nagaro, K. ;
Sambol, S. ;
Sears, P. ;
Shue, Y. -K. ;
Gerding, D. N. .
ANAEROBE, 2009, 15 (06) :234-236
[4]  
*CLIN LAB STAND I, 2009, M100S19 CLIN LAB STA
[5]   Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species [J].
Credito, KL ;
Appelbaum, PC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (11) :4430-4434
[6]   In vitro activities of OPT-80 and comparator drugs against intestinal bacteria [J].
Finegold, SA ;
Molitoris, D ;
Vaisanen, ML ;
Song, YL ;
Liu, CX ;
Bolaños, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (12) :4898-4902
[7]   Mutation in the Bacillus subtilis RNA polymerase β′ subunit confers resistance to lipiarmycin [J].
Gualtieri, M ;
Villain-Guillot, P ;
Latouche, J ;
Leonetti, JP ;
Bastide, L .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (01) :401-402
[8]  
Johnson AP, 2007, CURR OPIN INVEST DR, V8, P168
[9]   Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile [J].
Kyne, L ;
Hamel, MB ;
Polavaram, R ;
Kelly, CNP .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (03) :346-353
[10]   Clinical Outcomes, Safety, and Pharmacokinetics of OPT-80 in a Phase 2 Trial with Patients with Clostridium difficile Infection [J].
Louie, T. ;
Miller, M. ;
Donskey, C. ;
Mullane, K. ;
Goldstein, E. J. C. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (01) :223-228
12